Attrition in the Pharmaceutical Industry

Zusatztext

<p><b>With a focus on case studies of R&D programs in a variety of disease areas, the book highlights fundamental productivity issues the pharmaceutical industry has been facing and explores potential ways of improving research effectiveness and efficiency.</b></p><ul><li>Takes a comprehensive and holistic approach to the problems and potential solutions to drug compound attrition</li><li>Tackles a problem that adds billions of dollars to drug development programs and health care costs</li><li>Guides discovery and development scientists through R&D stages, teaching requirements and reasons why drugs can fail</li><li>Discusses potential ways forward utilizing new approaches and opportunities to reduce attrition</li></ul>

Autorenportrait

<p><b>Alexander Alex, Dr. rer. nat.</b>, is director of Evenor Consulting and has over 20 years' experience as consultant and as director and research fellow in drug discovery in the pharmaceutical industry.</p><p><b>C. John Harris, PhD</b>, is the director of cjh Consultants and has a successful track record in drug discovery, research management, small company fund-raising and start-ups.</p><p><b>Dennis A. Smith, PhD</b>, is an independent consultant with a long track record in drug discovery and development with an emphasis on metabolism and safety. He has published four books, including<i>Pharmacokinetics and Metabolism in Drug Design</i> (1st and 2nd editions) and<i>Reactive Drug Metabolites</i> published by Wiley.</p>

Weitere Details